Needham & Company LLC Reaffirms Buy Rating for Merit Medical Systems (NASDAQ:MMSI)

Merit Medical Systems (NASDAQ:MMSI)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports. They presently have a $108.00 price target on the medical instruments supplier’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 25.03% from the stock’s current price.

A number of other equities research analysts have also issued reports on MMSI. Zacks Research lowered Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Barrington Research restated an “outperform” rating and issued a $106.00 price objective on shares of Merit Medical Systems in a research report on Friday, November 14th. Robert W. Baird set a $108.00 price objective on Merit Medical Systems in a research note on Tuesday, December 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. Finally, Piper Sandler restated an “overweight” rating and issued a $109.00 target price (up from $105.00) on shares of Merit Medical Systems in a report on Friday, October 31st. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $105.88.

Merit Medical Systems Trading Down 7.3%

Shares of MMSI stock opened at $86.38 on Friday. The company has a current ratio of 4.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $87.03 and its 200-day moving average price is $86.58. Merit Medical Systems has a twelve month low of $78.12 and a twelve month high of $111.45. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 44.30, a PEG ratio of 2.51 and a beta of 0.62.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.10. The company had revenue of $384.16 million for the quarter, compared to the consensus estimate of $371.69 million. Merit Medical Systems had a net margin of 8.02% and a return on equity of 14.27%. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.86 earnings per share. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. As a group, equities analysts predict that Merit Medical Systems will post 3.37 earnings per share for the current year.

Insider Buying and Selling

In other news, Chairman Fred P. Lampropoulos sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $88.04, for a total transaction of $880,400.00. Following the completion of the transaction, the chairman owned 1,019,955 shares of the company’s stock, valued at $89,796,838.20. This represents a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 60,000 shares of company stock valued at $5,189,900. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Merit Medical Systems

A number of institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its stake in Merit Medical Systems by 2.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,973 shares of the medical instruments supplier’s stock worth $558,000 after purchasing an additional 131 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Merit Medical Systems by 55.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 134 shares during the last quarter. Norden Group LLC increased its holdings in shares of Merit Medical Systems by 5.7% during the 3rd quarter. Norden Group LLC now owns 2,536 shares of the medical instruments supplier’s stock worth $211,000 after buying an additional 137 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its position in shares of Merit Medical Systems by 7.2% in the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 2,225 shares of the medical instruments supplier’s stock worth $208,000 after buying an additional 149 shares during the period. Finally, SageView Advisory Group LLC boosted its holdings in Merit Medical Systems by 3.1% in the first quarter. SageView Advisory Group LLC now owns 5,065 shares of the medical instruments supplier’s stock valued at $535,000 after acquiring an additional 153 shares during the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Analysts reaffirmed Buy ratings and maintain upside — Needham reiterated a Buy with a $108 price target and Canaccord kept its Buy stance, signaling continued analyst confidence in MMSI’s growth prospects. Analyst Notes
• Positive Sentiment: Board leadership clarified — Merit appointed long-time director F. Ann Millner as Chair of the Board effective Jan. 5, 2026, which investors typically view as governance continuity and reduced uncertainty at the top. Merit Medical Appoints F. Ann Millner
• Positive Sentiment: Preliminary Q4 revenue roughly in line-to-slightly-above consensus — Merit provided a projected preliminary unaudited Q4 revenue range (~$389M–$395M) that sits around analyst estimates, supporting its operating momentum heading into FY2026. Preliminary Q4 Revenue
• Neutral Sentiment: Technical backdrop mixed — Shares recently crossed above the 200-day moving average, a constructive technical sign, but the move may also invite profit-taking by short-term traders. Technical Note
• Negative Sentiment: No clear EPS guidance in the Q4 update and elevated volume — The company’s Q4 release omitted a firm EPS number, which can create uncertainty; combined with higher-than-average trading volume, that likely pressured the stock as some investors reduced exposure despite positive revenue and analyst commentary.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.